NDC 61958-0101

Vistide

Cidofovir

Vistide is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences, Inc.. The primary component is Cidofovir.

• Product ID: 61958-0101_cc1a8d88-6b17-49dd-9e47-a19a3a4b0f44
• NDC: 61958-0101
• Product Type: Human Prescription Drug
• Proprietary Name: Vistide
• Generic Name: Cidofovir
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 1996-06-26
• Marketing Category: NDA / NDA
• Application Number: NDA020638
• Labeler Name: Gilead Sciences, Inc.
• Substance Name: CIDOFOVIR
• Active Ingredient Strength: 75 mg/mL
• Pharm Classes: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [EXT]
• NDC Exclude Flag: E
• Listing Certified Through: 2018-12-31

Packaging

NDC 61958-0101-1

1 VIAL, SINGLE-USE in 1 CARTON (61958-0101-1) > 5 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 1996-06-26
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 61958-0101-1 [61958010101]

Vistide INJECTION

• Marketing Category: NDA
• Application Number: NDA020638
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 1996-06-26
• Inactivation Date: 2020-01-31

Drug Details

Active Ingredients

Ingredient	Strength
CIDOFOVIR	75 mg/mL

OpenFDA Data

• SPL SET ID: 90639fc6-0295-4115-98f0-054b783850ce
• Manufacturer:
  • Gilead Sciences, Inc.
• UNII:
  • JIL713Q00N
• RxNorm Concept Unique ID - RxCUI:
  • 199388
  • 211248

Pharmacological Class

• Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
• DNA Polymerase Inhibitors [MoA]
• Nucleoside Analog [EXT]